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Evidence of virus-induced systemic lupus erythematosus
(SLE) is illustrated by documentation of a 10-year old girl
who developed SLE (satisfying AAA criteria) soon after
infection with Epstein-Barr virus (EBV) infection. She
showed complete remission 24 months later following an
aggressive course of immunosuppressive therapy. The
appearance and disappearance of serological evidence of
EBV infection, followed by the onset and complete clinical
and serological remission of SLE, which in this case had
unusually mild complications, suggest a causal
relationship.
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Serological tests for EBV showed a positive IgM anti-viral
capsid antigen antibody to EB\/, and an absence of antibody
to EB nuclear antigen that suggested an acute EBV infection
(Table I). Three weeks later she developed severe headaches
and anorexia; the adenopathy persisted. The week after this
she developed vasculitic lesions on the palms and soles,
arthritis of the right knee and moderate hypertension.
Urinary dipstick testing showed proteinuria + + and
haematuria + +. A screen for auto-immune diseases
revealed that antinuclear antibodies were positive in a
dilution of 1:50; the titre SUbsequently rose to 1:3 200. SLE
was confirmed by the presence of dsDNA auto-antibodies of
the homogeneous type. In addition, the extractable nuclear
antigen was positive. Other laboratory investigations showed
the following: erythrocyte sedimentation rate 60 mm/h;
complement (C3 fraction) 0,31 gll (normal 0,83 - 1,77 gll);
(C4 fraction) < 0,08 gll (normal 0,72 - 0,36 gll); white cell
count 2,9 x 10· /I and severe neutropenia. Her renal biopsy
revealed a diffuse membranoproliferative grade VI nephritis.'
Repeat testing for EBV showed IgG antibodies strongly
positive for viral capsid antigen (1 :640); IgM antibody was
now negative and early antigen positive (1 :40) (Table I). This
confirmed recent exposure to EBV.
Table I. Serological and clinical events in a 10-year-old girl with
EBV infection and SLE
ND = not done; + = present; - = absent.
• Complement (C3 fraction).
Except for an exacerbation of her disease 3 months after
commencement of therapy, she showed steady
improvement with complete resolution of constitutional
symptoms as well as disappearance of urinary sediment.
Her drug dosages were gradually reduced and eventually
stopped 24 months after the onset of her disease. Repeat
laboratory investigations showed absence of all auto-
antibodies and acute phase reactants with
normocomplementaemia. Repeat serological tests for EBV
were negative. At present, 37 months after the appearance




























































The causation of systemic lupus erythematosus (SLE)
remains enigmatic although the pathogenesis is
multifactorial. A number of agents appear to trigger a series
of events which culminates in the immune dysregulation
typical of this disease.'" Some indirect support for viruses as
triggering agents has been provided by serological studies
which have shown high frequencies and elevated titres of
Epstein-Barr virus (EBV) antibodies in sera from patients
with connective tissue disease.3.• However, the link between
SLE and EBV infection remains tenuous. We now report
what we believe to be the first case (based on a fruitless
Medline search) of EBV infection associated with SLE in a
10-year-old Indian girl. The appearance and disappearance
of serological evidence of EBV infection coincided with the
onset and remission of SLE.
The patient presented with a history of fever, sore throat,
lethargy and cervical lymphadenopathy. A full blood count
showed the follOWing: haemoglobin 11 ,3 gll; platelets
251 x 10· 11; and leucocytes 3,14 x 10· 1I with a differential
count of 52% neutrophils, 38% Iymphocytes, 8,5%
monocytes and 1,5% eosinophils. At this stage, clinical
diagnosis of infectious mononucleosis was entertained
despite the presence of leucopenia. Eleven days later she
developed a generalised faint maculopapular rash; the fever
and lymphadenopathy remained unchanged.
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of SLE, she is in complete clinical remission with no
laboratory evidence of disease activity. The development of
EBV antibodies and auto-antibodies together with clinical
events are shown in Table I.
Discussion
Within 12 weeks of an episode of EBV infection, the child
described here developed clinical and laboratory features
consistent with ARA criteria for the diagnosis of SLE. The
continuity between her EBV infection and the development
of SLE makes it highly likely that the virus served as a
trigger factor. One drawback of the viral hypothesis is that
we have only serological evidence for acute infection with
EBV, as viral culture was not performed. Both SLE and EBV
infection share similar immune dysregulation. Altered T-cell-
mediated control allows the production of auto-antibodies
by the EBV-induced B cells which remain latently infected.
Patients with SLE have been shown to have high levels of
antibodies to the EBV capsid antigens," nuclear antigens'
and early antigens.5 This may be an epiphenomenon.
However, there is a molecule link between the EBV-induced
nuclear antigen, EBNA-1, and the Sm-D auto-antigens in the
sera of patients with SLE. 5
In developing countries like South Africa, the typical
syndrome is rare as virus transmission occurs early in
infancy and childhood. Our patient presented typically but
had a low white cell count, which is less common? The
disease did not settle within a month but progressed to SLE:
Although there is overlap in clinical manifestations of both
diseases, SLE was confirmed serologically and by ARA
criteria. Over a few months the clinical and laboratory
indices of both SLE and EBV resolved and all drug therapy
was discontinued. At presentation her growth parameters
were normal and she maintained her growth pattern
throughout her illness unlike most children with SLE, who
are underweight and stunted. This also suggests a transient
immune disturbance. Quiescent ongoing renal disease in the
face of inactive SLE is a possibility that has to be
excluded. 'o Delayed relapses after a protracted remission are
also possible since the disease is known to run a course of
exacerbations and remissions. It could be argued that the
child had only SLE, and that the EBV antibodies were due to
nonspecific polyclonal B-cell stimulation. Although SLE is
rare in the Third World, our experience is that the disease is
severe, often fatal and rarely remits either spontaneously or
with intensive therapy. At present the child is in prolonged
clinical remission, an unusual finding in childhood SLE
where the disease is known to run a more aggressive
course.
Conclusion
This is the best-documented case of EBV-induced SLE. The
diagnosis of both diseases is reliable, but that for EBV could
have been strengthened by viral culture. That the diseases
were causally related with more than a simple association is
evident in the close temporal relationship between the
sequential acquisition and disappearance of both diseases,
and the unusually mild clinical complications of SLE.
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The authors subsequently treated a 7-year-old black boy
with SLE, who was also diagnosed as having acute EBV
infection on the basis of IGM-positive EBV antibodies. This
serves as further corroborative evidence of EBV's being a
possible trigger agent for the development of SLE.
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100 years ago . ..
The Corporation of Bloemfontein has imposed a tax of
7s. 6d. on bachelors above 18, to assist in covering the
expenses of the small-pox epidemic. It may bring in cash,
but we doubt the ulterior effect. It is cheap at that. .
A death from chloroform is reported from the New
Somerset Hospital. It is regrettable, but no more an
indication of the danger attending the administration than a
death in a railway or carriage accident is of the danger of
travelling by rail or by road.
(5 A Medical Journal, September 1895, p. 152).
-
